Wells Fargo & Company Increases Integra LifeSciences (NASDAQ:IART) Price Target to $15.00

Integra LifeSciences (NASDAQ:IART) had its price target boosted by equities research analysts at Wells Fargo & Company from $12.00 to $15.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the life sciences company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 12.28% from the stock’s current price.

A number of other analysts have also recently commented on IART. Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Argus restated a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Citigroup dropped their price target on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Finally, Truist Financial dropped their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $14.80.

Integra LifeSciences Stock Performance

Shares of IART stock traded up $0.14 during trading on Wednesday, reaching $13.36. 163,476 shares of the company’s stock traded hands, compared to its average volume of 809,029. The company has a market capitalization of $1.04 billion, a P/E ratio of -1.98 and a beta of 1.08. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. The firm’s 50-day moving average is $10.11 and its 200 day moving average is $11.73. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $16.49.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The company had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts expect that Integra LifeSciences will post 2.34 EPS for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC purchased a new stake in Integra LifeSciences in the 4th quarter worth approximately $25,000. Osaic Holdings Inc. lifted its stake in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. GAMMA Investing LLC lifted its stake in Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Integra LifeSciences in the 4th quarter worth approximately $124,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — quarterly EPS of $0.54 topped consensus ~$0.41 and revenue of ~$392M exceeded estimates, showing modest growth versus year‑ago figures. Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Full‑year EPS guidance raised to $2.40–$2.50, above consensus (~$2.35), giving longer‑term earnings visibility and suggesting management expects recovery/growth later in the year. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Leadership change announced — Stuart Essig named next President & CEO and Michael McBreen appointed Chief Commercial Officer; this is material but the impact depends on execution and strategy under new leadership. Integra LifeSciences Announces Leadership Transition
• Neutral Sentiment: Investors can review management commentary and detail in the earnings call transcript and slide deck for product/segment color that could drive forward guidance revisions. Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q2 guidance came in below Street expectations — management gave Q2 EPS of $0.44–$0.52 (consensus ~$0.53) and revenue guidance $410–$425M (vs. ~$425.3M consensus), creating near‑term growth risk and the main reason for the muted/negative market reaction. Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.